Danaher Co. (NYSE:DHR) Shares Acquired by Naviter Wealth LLC

Naviter Wealth LLC raised its position in shares of Danaher Co. (NYSE:DHR) by 19.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,305 shares of the conglomerate’s stock after acquiring an additional 1,199 shares during the quarter. Naviter Wealth LLC’s holdings in Danaher were worth $1,692,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Banco Santander S.A. acquired a new position in shares of Danaher during the third quarter valued at approximately $683,000. First Citizens Bank & Trust Co. increased its stake in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares during the last quarter. Cercano Management LLC increased its stake in Danaher by 11.4% during the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after acquiring an additional 20,715 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its stake in Danaher by 4.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after acquiring an additional 142 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR traded up $0.83 during trading on Monday, hitting $247.41. 738,761 shares of the stock were exchanged, compared to its average volume of 2,760,281. The company has a fifty day moving average price of $248.87 and a two-hundred day moving average price of $231.27. The company has a market cap of $183.25 billion, a PE ratio of 42.12, a P/E/G ratio of 3.80 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.36 EPS. On average, analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were paid a $0.27 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity at Danaher

In related news, EVP Joakim Weidemanis sold 22,433 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total value of $5,618,569.18. Following the sale, the executive vice president now owns 90,412 shares of the company’s stock, valued at approximately $22,644,589.52. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, EVP Joakim Weidemanis sold 22,433 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total value of $5,618,569.18. Following the sale, the executive vice president now owns 90,412 shares of the company’s stock, valued at approximately $22,644,589.52. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 106,565 shares of company stock valued at $26,641,364. 11.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Barclays raised their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Bank of America raised their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and raised their price target for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada lifted their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $269.64.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.